Home

Tillman U. Gerngross

CIK 1722061 · Chief Executive Officer · last filed 2023-06-15

Tillman U. Gerngross is a Chief Executive Officer who has filed 12 SEC Form 4 insider transactions across 3 companies since 2017. The most recent filing, for ALEC, was dated Jun 15, 2023. Across all open-market trades the lifetime net is +$2.0M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $6.5M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$6.53M

Companies

3

Total Filings

12

Lifetime Open-Market Net

$2.00M

Filer Profile

Reported Address
C/O ARSANIS, INC.
890 WINTER STREET, SUITE 230
WALTHAM, MA 02451
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ALEC Director 2,644,319 $2.47 $6.53M $0 6 2023-06-15
Invivyd, Inc. (ADGI) Delisted Chief Executive Officer 27,845,995 $4.64 $129.21M $0 2 2022-02-01
X4 Pharmaceuticals, Inc (ASNS) Delisted Director 321 $0.08 $25 $2.00M 4 2018-06-07

Recent Filings

12 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-06-15 ALEC Grant (A) +26,250 $0 EDGAR
2022-06-21 ALEC Grant (A) +9,459 $0 EDGAR
2022-02-01 Invivyd, Inc. (ADGI) Delisted Grant (A) — $0 EDGAR
2021-08-12 Invivyd, Inc. (ADGI) Delisted Conv (C) +25,860,700 $0 EDGAR
2021-06-22 ALEC Grant (A) — $0 EDGAR
2020-05-13 ALEC Grant (A) — $0 EDGAR
2019-05-14 ALEC Grant (A) — $0 EDGAR
2019-02-11 ALEC Conv (C) +427,292 $0 EDGAR
2018-06-07 X4 Pharmaceuticals, Inc (ASNS) Delisted Grant (A) — $0 EDGAR
2018-03-05 X4 Pharmaceuticals, Inc (ASNS) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 12
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.